InDex Pharmaceuticals Holding announced in April 2022 that after more than seven years as CEO, Peter Zerhouni has decided to leave his position.
The company’s CFO Johan Giléus has been appointed acting CEO while a new CEO is being recruited, and he will also continue as CFO.
“With the drug candidate cobitolimod in phase III, a clear plan to market, and a solid financial position, InDex stands stronger than ever,” says Wenche Rolfsen, chairman of InDex Pharmaceuticals. “I want to thank Peter for his contribution in building the company and for his good collaboration. I wish him all the best.”
“It has been a rewarding journey and I am very proud of what the InDex team has accomplished during my time as CEO,” says Peter Zerhouni.
Peter Zerhouni will be available to the board during his notice period.
Photo of Peter Zerhouni: Kristian Pohl